Handa Pharmaceuticals, Inc. (6620.TWO)
TWD 51.5
(-2.83%)
TWD 51.5
(-2.83%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 668.36 Million | -211.57 Million | -179.23 Million | -308.47 Million | - |
| Net Income | 792.48 Million | -43.15 Million | -260.8 Million | -320.44 Million | - |
| Depreciation & Amortization | 12.44 Million | 15.18 Million | 35.16 Million | 55.99 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 8.46 Million | 112 Thousand | 257 Thousand | 644 Thousand | - |
| Change in working capital | -124.32 Million | -181.3 Million | 46.65 Million | -49.46 Million | - |
| Other non-cash items | -17.93 Million | -221 Thousand | -57 Thousand | -2.56 Million | - |
| Investing Cash Flow | -1.66 Billion | 29.5 Million | -2.91 Million | 181.72 Million | - |
| Investments in PPE | -944 Thousand | -758 Thousand | -7.15 Million | -7.4 Million | - |
| Acquisitions | -10.97 Million | - | - | - | - |
| Investment purchases | -1.75 Billion | -7.75 Million | -33.32 Million | -102.86 Million | - |
| Sales/Maturities of investments | 101.97 Million | 38.46 Million | 37.31 Million | 292.07 Million | - |
| Other Investing Activities | - | -447 Thousand | 227 Thousand | -79 Thousand | 4.55 Million |
| Financing Cash Flow | 1.3 Billion | 313.64 Million | 162.9 Million | -5.36 Million | - |
| Debt repayment | - | - | - | - | -2.5 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 1.31 Billion | 320.83 Million | 170.67 Million | 2.74 Million | - |
| Other Financing Activities | 8000.00 | - | - | - | - |
| Accounts receivables | -216.72 Million | - | - | - | - |
| Accounts payables | 8.34 Million | - | - | - | - |
| Inventory | - | 10.1 Million | - | - | - |
| Other working capital | 92.4 Million | - | - | - | - |
| Cash at beginning of period | 365.91 Million | 263.3 Million | 280.11 Million | 410.48 Million | - |
| Cash at end of period | 667.04 Million | 365.91 Million | 263.3 Million | 280.11 Million | - |
| Capital Expenditure | -944 Thousand | -758 Thousand | -7.15 Million | -7.4 Million | - |
| Effect of forex changes on cash | -8.34 Million | -28.97 Million | 2.43 Million | 1.74 Million | - |
| Net cash flow / Change in cash | 301.13 Million | 102.6 Million | -16.8 Million | -130.36 Million | - |
| Free Cash Flow | 667.41 Million | -212.32 Million | -186.38 Million | -315.88 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 109.49 Million | 166.86 Million | 792.48 Million | 170.95 Million | 139.81 Million | 240.13 Million |
| Depreciation & Amortization | 2.5 Million | 2.24 Million | 12.44 Million | 2.67 Million | 2.8 Million | 3.31 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 6.81 Million | 6.6 Million | 8.46 Million | 6.97 Million | 1.47 Million | 1000.00 |
| Change in working capital | 18.64 Million | 135.55 Million | -124.32 Million | 7.12 Million | 108.85 Million | -58.99 Million |
| Other non-cash items | -15.34 Million | -13.77 Million | -17.93 Million | -10.98 Million | -5.65 Million | -1.35 Million |
| Investing Cash Flow | 137.64 Million | -169.63 Million | -1.66 Billion | -932.47 Million | -559.53 Million | -171.86 Million |
| Investments in PPE | -1.47 Million | - | -944 Thousand | -199 Thousand | - | -117 Thousand |
| Acquisitions | - | - | -10.97 Million | - | - | - |
| Investment purchases | -260.11 Million | -169.63 Million | -1.75 Billion | -1.03 Billion | -559.53 Million | -160.77 Million |
| Sales/Maturities of investments | 400 Million | - | 101.97 Million | 101.97 Million | - | - |
| Other Investing Activities | -765 Thousand | - | - | - | - | - |
| Financing Cash Flow | -139.56 Million | -1.3 Million | 1.3 Billion | 11 Thousand | 1.3 Billion | 6.04 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -141.08 Million | - | - | - | - | - |
| Common Stock Issuance | 2.96 Million | 157 Thousand | 1.31 Billion | 1.48 Million | 1.3 Billion | 8.02 Million |
| Other Financing Activities | -1.43 Million | - | 8000.00 | - | - | - |
| Accounts receivables | 19.81 Million | - | - | - | - | - |
| Accounts payables | -2.42 Million | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.25 Million | - | - | - | - | - |
| Cash at beginning of period | 825.5 Million | 667.04 Million | 365.91 Million | 1.42 Billion | 438.05 Million | 430.11 Million |
| Cash at end of period | 835.32 Million | 825.5 Million | 667.04 Million | 667.04 Million | 1.42 Billion | 438.05 Million |
| Capital Expenditure | -1.47 Million | - | -944 Thousand | -199 Thousand | - | -117 Thousand |
| Effect of forex changes on cash | 6.03 Million | 18.03 Million | -8.34 Million | -8.91 Million | 248 Thousand | -2.48 Million |
| Net cash flow / Change in cash | 9.81 Million | 158.46 Million | 301.13 Million | -759.55 Million | 988.53 Million | 7.94 Million |
| Free Cash Flow | 4.21 Million | 311.37 Million | 667.41 Million | 181.63 Million | 247.61 Million | 176.13 Million |
ETAOF
000150
LBL
FRST
MEVA
ARL